Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target
Immune Network
; : e8-2021.
Artigo
em Inglês
| WPRIM (Pacífico Ocidental)
| ID: wpr-874613
Biblioteca responsável:
WPRO
ABSTRACT
The global crisis caused by the coronavirus disease 2019 (COVID-19) led to the most significant economic loss and human deaths after World War II. The pathogen causing this disease is a novel virus called the severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). As of December 2020, there have been 80.2 million confirmed patients, and the mortality rate is known as 2.16% globally. A strategy to protect a host from SARS-CoV-2 is by suppressing intracellular viral replication or preventing viral entry. We focused on the spike glycoprotein that is responsible for the entry of SARS-CoV-2 into the host cell. Recently, the US Food and Drug Administration/EU Medicines Agency authorized a vaccine and antibody to treat COVID-19 patients by emergency use approval in the absence of long-term clinical trials. Both commercial and academic efforts to develop preventive and therapeutic agents continue all over the world. In this review, we present a perspective on current reports about the spike glycoprotein of SARS-CoV-2 as a therapeutic target.
Texto completo:
Disponível
Contexto em Saúde:
Agenda de Saúde Sustentável para as Américas
/
ODS3 - Meta 3.3 Acabar com as doenças tropicais negligenciadas e combater as doenças transmissíveis
Problema de saúde:
Objetivo 9: Redução de doenças não transmissíveis
/
COVID-19
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Inglês
Revista:
Immune Network
Ano de publicação:
2021
Tipo de documento:
Artigo